Literature DB >> 21145824

Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.

Tae-Hee Um1, Haeryoung Kim, Bong-Kyeong Oh, Myoung Soo Kim, Kyung Sik Kim, Guhung Jung, Young Nyun Park.   

Abstract

BACKGROUND & AIMS: The concept of multistep hepatocarcinogenesis has been well-established, and an accumulation of methylating events has recently been demonstrated; however, the methylation status of low-grade dysplastic nodules (LGDN), high-grade dysplastic nodules (HGDN), and the recently introduced early hepatocellular carcinoma (eHCC) in hepatitis B virus (HBV)-related hepatocarcinogenesis has not yet been studied.
METHODS: One hundred thirty-three DNA samples (45 cirrhotic nodules, 29 LGDNs, 13 HGDNs, 14 eHCCs, and 32 progressed HCCs (pHCCs)) from HBV-infected resected livers were subjected to MethyLight analysis for nine CpG island loci (APC, RASSF1A, SOCS1, P16, COX2, SPRY2, PTEN, GNMT, and ERK), and COX2, RASSF1A, and SOCS1 protein expression status was analyzed by immunohistochemistry. The methylation status of each sample was correlated with the clinicopathological features.
RESULTS: APC, RASSF1A, and SOCS1 were methylated in 20 (44.4%), 25 (55.6%), and 13 (28.9%) of 45 cirrhosis samples, and APC (p=0.0008) and SOCS1 (p=0.0187) methylation were more frequent in dysplastic nodules and HCCs. APC (p=0.001) and RASSF1A (p=0.019) methylation levels were significantly increased from cirrhosis to LGDN. SOCS1 methylation gradually increased along multistep hepatocarcinogenesis, peaked at eHCC and decreased significantly in pHCCs (p=0.039). By contrast, p16 and COX2 was only methylated in dysplastic nodules and HCCs, with a stepwise increase up to pHCCs. As a whole, the frequency of methylation was highest in eHCCs. A stepwise decrease in COX2, RASSF1A, and SOCS1 protein expression was demonstrated.
CONCLUSIONS: A general stepwise increase in methylating events is seen during HBV-related multistep hepatocarcinogenesis, and epigenetic changes may occur predominantly in the earlier stages of HCC development.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145824     DOI: 10.1016/j.jhep.2010.08.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  76 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

3.  Loss of GATA5 expression due to gene promoter methylation induces growth and colony formation of hepatocellular carcinoma cells.

Authors:  Lei Xia; Yan Gong; Aiqun Zhang; Shouwang Cai; Qiang Zeng
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

Review 4.  Environmental epigenetics and its implication on disease risk and health outcomes.

Authors:  Shuk-Mei Ho; Abby Johnson; Pheruza Tarapore; Vinothini Janakiram; Xiang Zhang; Yuet-Kin Leung
Journal:  ILAR J       Date:  2012

Review 5.  Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.

Authors:  Zdenko Herceg; Marie-Pierre Lambert; Karin van Veldhoven; Christiana Demetriou; Paolo Vineis; Martyn T Smith; Kurt Straif; Christopher P Wild
Journal:  Carcinogenesis       Date:  2013-06-07       Impact factor: 4.944

Review 6.  From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence.

Authors:  Gayatri Ramakrishna; Archana Rastogi; Nirupama Trehanpati; Bijoya Sen; Ritu Khosla; Shiv K Sarin
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

7.  Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.

Authors:  Xueping Qiu; Bo Hu; Yifang Huang; Yunte Deng; Xuebin Wang; Fang Zheng
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

Review 8.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

Review 9.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

10.  Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.

Authors:  Jens U Marquardt; Kerstin Fischer; Katharina Baus; Anubha Kashyap; Shengyun Ma; Markus Krupp; Matthias Linke; Andreas Teufel; Ulrich Zechner; Dennis Strand; Snorri S Thorgeirsson; Peter R Galle; Susanne Strand
Journal:  Hepatology       Date:  2013-07-30       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.